DDInter1852 DDInter336
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Treprostinil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Celecoxib
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is regulated by {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Celecoxib
Treprostinil {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Celecoxib
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Celecoxib (Compound)
Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Treprostinil (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoricoxib (Compound) and PTGS2 (Gene) is upregulated by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Celecoxib (Compound)
Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is regulated by ORM1 (Gene) and ORM1 (Gene) is bound by Celecoxib (Compound)
Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Celecoxib (Compound)
Treprostinil (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Celecoxib (Compound)